Login Register
icon_bulk_orderBulk order Acrobiosystems for English
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CD52


Brief Information

Name:CAMPATH-1 antigen
Target Synonym:Epididymis Secretory Sperm Binding Protein Li 171mP,CD52 Antigen (CAMPATH-1 Antigen),Epididymal Secretory Protein E5,He5,CDW52 Antigen (CAMPATH-1 Antigen),CD52 Antigen,HEL-S-171mP,EDDM5,CD52,CDw52,Cambridge pathology 1 antigen,Human epididymis-specific protein 5,CAMPATH-1 antigen,CD52 Molecule
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:3
Lastest Research Phase:Approved

Product ListCompare or Buy

Part of Bioactivity data


Anti-Human CD52 MAb (Human IgG1) captured on CM5 chip via anti-human IgG Fc antibodies surface can bind Biotinylated Human CD52, His,Avitag (Cat. No. CD2-H82E8) with an affinity constant of 71.8 nM as determined in a SPR assay (Biacore T200) (Routinely tested).


Loaded Biotinylated Human CD52, His,Avitag (Cat. No. CD2-H82E8) on SA Biosensor, can bind Anti-Human CD52 MAb (Human IgG1) with an affinity constant of 137 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Synonym Name

CDW52,HE5,CD52,CAMPATH-1 antigen


CAMPATH-1 antigen, also known as cluster of differentiation 52 (CD52), is a glycoprotein that in humans is encoded by the CD52 gene.It is widely expressed on the cell surface of immune cells, such as mature lymphocytes, natural killer cells (NK), eosinophils, neutrophils, monocytes/macrophages, and dendritic cells (DCs).ligation of cell surface CD52 molecules may offer costimulatory signals for T-cell activation and proliferation.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Alemtuzumab LDP-03; GZ-402673 Approved Genzyme Corp, Bayer AG Campath, Lemtrada, MabCampath Japan Leukemia, Lymphocytic, Chronic, B-Cell Sanofi 2001-05-07 Multiple Sclerosis; Leukemia, Lymphocytic, Chronic, B-Cell; Fallopian Tube Neoplasms; Lymphoma, Non-Hodgkin; Lymphoma; Waldenstrom Macroglobulinemia; Leukemia, Myeloid, Acute; Peritoneal Neoplasms; Pancytopenia; Multiple Sclerosis, Relapsing-Remitting; Myelodysplastic Syndromes; Graft vs Host Disease; Bone marrow transplant rejection; Ovarian Neoplasms; Hematologic Neoplasms; Rejection of renal transplantation; Diabetes Mellitus, Type 1 Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Recombinant anti-CD52 humanized monoclonal antibody (Lanzhou Institute Of Biological Products/Shanghai Taiyin Biotechnology) Phase 1 Clinical Lanzhou Institute Of Biological Products Co Ltd, Shanghai Taiyin Biotechnology Co Ltd Leukemia, B-Cell; Lymphoma, Non-Hodgkin; Leukemia, Prolymphocytic, T-Cell; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Prolymphocytic Details
Alemtuzumab biosimilar (Zhangjiang Biotechnology) Phase 2 Clinical Shanghai Zhangjiang Biotechnology Co Ltd Leukemia, Lymphocytic, Chronic, B-Cell Details
Alemtuzumab biosimilar(BioXpress) BX-1523; BXT-1523 Clinical Bioxpress Therapeutics Sa Multiple Sclerosis; Leukemia, B-Cell Details
ALLO-647 ALLO-647 Phase 2 Clinical Allogene Therapeutics Inc Lymphoma, B-Cell; Carcinoma, Renal Cell; Multiple Myeloma; Lymphoma, Follicular Details

This web search service is supported by Google Inc.

Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message